IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors

Tyrosine kinase inhibitors (TKIs) have dramatically improved the survival in chronic myeloid leukemia (CML), but residual disease typically persists even after prolonged treatment. Several lines of evidence suggest that TKIs administered to CML patients upregulate interferon γ (IFNγ) production, whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ujvari, Dorina, Malyukova, Alena, Zovko, Ana, Yektaei-Karin, Elham, Madapura, Harsha S, Keszei, Marton, Nagy, Noemi, Lotfi, Kourosh, Björn, Niclas, Wallvik, Jonas, Stenke, Leif, Salamon, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377247/
https://www.ncbi.nlm.nih.gov/pubmed/35979386
http://dx.doi.org/10.1080/2162402X.2022.2109861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377247/
https://www.ncbi.nlm.nih.gov/pubmed/35979386
http://dx.doi.org/10.1080/2162402X.2022.2109861

Ejemplares similares